Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's disease Coronavirus More reports can be found here BioWorld
A phase 2 study of semaglutide 2.4 mg in patients with NASH-related cirrhosis found improvements in metabolic markers and liver fat but no significant fibrosis regression [7]
Due to historically higher rates of side effects (especially blood pressure elevation) with intranasal delivery, the injection is generally preferred for both efficacy and safety
If indigestion is problematic, discuss with your GP whether remaining at a lower dose for a longer period or slowing the titration might be appropriate
The majority of the participants were prescribed to a regimen involving 7.2 mg weekly doses of semaglutide medication, triple the standard dose
